The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas
Open accessAbstract
BACKGROUND: The role of prophylactic antibacterial agents after chemotherapy remains controversial. METHODS: We conducted a randomized, double-blind, placebo-controlled trial in patients who were receiving cyclic chemotherapy for solid tumors or lymphoma and who were at risk for temporary, severe neutropenia (fewer than 500 neutrophils per cubic millimeter). Patients were randomly assigned to receive either 500 mg of levofloxacin once daily or matching placebo for seven days during the expected neutropenic period. The primary outcome was the incidence of clinically documented febrile episodes (temperature of more than 38 degrees C) attributed to infection. Secondary outcomes included the incidence of all probable infections, severe infections, and hospitalization but did not include a systematic evaluation of antibacterial resistance. RESULTS: A total of 1565 patients underwent randomization (784 to placebo and 781 to levofloxacin). The tumors included breast cancer (35.4 percent), lung cancer (22.5 percent), testicular cancer (14.4 percent), and lymphoma (12.8 percent). During the first cycle of chemotherapy, 3.5 percent of patients in the levofloxacin group had at least one febrile episode, as compared with 7.9 percent in the placebo group (P<0.001). During the entire chemotherapy course, 10.8 percent of patients in the levofloxacin group had at least one febrile episode, as compared with 15.2 percent of patients in the placebo group (P=0.01); the respective rates of probable infection were 34.2 percent and 41.5 percent (P=0.004). Hospitalization was required for the treatment of infection in 15.7 percent of patients in the levofloxacin group and 21.6 percent of patients in the placebo group (P=0.004). The respective rate of severe infection was 1.0 percent and 2.0 percent (P=0.15), with four infection-related deaths in each group. An organism was isolated in 9.2 percent of probable infections. CONCLUSIONS: Among patients receiving chemotherapy for solid tumors or lymphoma, the prophylactic use of levofloxacin reduces the incidence of fever, probable infection, and hospitalization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
Outpatient antibiotic use in Europe and association with resistance: a cross-national database study
Goossens, H., Ferech, M., Vander Stichele, R., & Elseviers, M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17907-0 · Cited by 3,359
Klastersky, J., Paesmans, M., Rubenstein, E. B., Boyer, M., Elting, L., Feld, R., Gallagher, J., Herrstedt, J., Rapoport, B., Rolston, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.3038 · Cited by 1,171
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3558 · Cited by 1,044
1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever
Hughes, W. T., Armstrong, D., Bodey, G. P., Brown, A. E., Edwards, J. E., Feld, R., Pizzo, P., Rolston, K. V. I., Shenep, J. L., & Young, L. S. (1997) · Clinical Infectious Diseases · doi:10.1086/513764 · Cited by 672
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
Bucaneve, G., Micozzi, A., Menichetti, F., Martino, P., Dionisi, M. S., Martinelli, G., Allione, B., D'Antonio, D., Buelli, M., Nosari, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044097 · Cited by 648
Freifeld, A., Marchigiani, D., Walsh, T., Chanock, S., Lewis, L., Hiemenz, J., Hiemenz, S., Hicks, J. E., Gill, V., Steinberg, S. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907293410501 · Cited by 402
Kern, W. V., Cometta, A., de Bock, R., Langenaeken, J., Paesmans, M., Zanetti, G., Calandra, T., Glauser, M. P., Crokaert, F., Klastersky, J., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907293410502 · Cited by 370
Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis.
Engels, E. A., Lau, J., & Barza, M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1179 · Cited by 256
Prophylaxis with Fluoroquinolones for Bacterial Infections in Neutropenic Patients: A Meta-Analysis
Cruciani, M., Rampazzo, R., Malena, M., Lazzarini, L., Todeschini, G., Messori, A., & Concia, E. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.4.795 · Cited by 250
Cited by
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
Cheng, L., Albers, P., Berney, D. M., Feldman, D. R., Daugaard, G., Gilligan, T., & Looijenga, L. H. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0029-0 · Cited by 462
Flowers, C. R., Seidenfeld, J., Bow, E. J., Karten, C., Gleason, C., Hawley, D. K., Kuderer, N. M., Langston, A. A., Marr, K. A., Rolston, K. V. I., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8661 · Cited by 448
Management of febrile neutropenia: ESMO Clinical Practice Guidelines
de Naurois, J., Novitzky-Basso, I., Gill, M. J., Marti Marti, F., Cullen, M. H., & Roila, F. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq196 · Cited by 435
Self-citationGafter-Gvili, A., Fraser, A., Paul, M., Vidal, L., Lawrie, T. A., van de Wetering, M. D., Kremer, L. C., & Leibovici, L. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004386.pub3 · Cited by 383
Metadata
- Authors
- Cullen, M., Steven, N., Billingham, L., Gaunt, C., Hastings, M., Simmonds, P., Stuart, N., Rea, D., Bower, M., Fernando, I., Huddart, R., Gollins, S., & Stanley, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-09-08
- Volume
- 353
- Issue
- 10
- Pages
- 988-998
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2093205745
- Cited by
- 422
- References
- 13
- FWCI
- 15.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas. https://app.cochat.ai/papers/10.1056/nejmoa050078
- The paper
- Cullen, M., Steven, N., Billingham, L., Gaunt, C., Hastings, M., Simmonds, P., Stuart, N., Rea, D., Bower, M., Fernando, I., Huddart, R., Gollins, S., & Stanley, A. (2005). Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas. New England Journal of Medicine. https://doi.org/10.1056/nejmoa050078
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.